We are live on ! Find out more
QUSVM

Qiming U.S. Ventures Management Portfolio holdings

AUM $55.6M
1-Year Est. Return 98.09%
This Fund
S&P 500
This Quarter Est. Return
+3.04%
1 Year Est. Return
+98.09%
3 Year Est. Return
+1,484.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$51.1M
AUM Growth
-$218K
Cap. Flow
-$350K
Cap. Flow %
-0.68%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
HLVX
HilleVax
HLVX
+$350K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JSPR icon
1
Jasper Therapeutics
JSPR
$22.4M
$19.9M 38.83%
928,964
– –
TRML
2
DELISTED
Tourmaline Bio
TRML
$15M 29.41%
741,691
– –
KRRO icon
3
Korro Bio
KRRO
$153M
$14M 27.4%
368,085
– –
VTYX
4
DELISTED
Ventyx Biosciences
VTYX
$903K 1.77%
412,225
– –
HLVX
5
DELISTED
HilleVax
HLVX
$771K 1.51%
372,615
-186,308
-33% -$350K
KZR
6
DELISTED
Kezar Life Sciences
KZR
$557K 1.09%
82,871
– –

Similar funds

CCCPV
Castle Creek Capital Partners VI San Diego, California $55.9M AUM 7.91% 1-Year Est. Return
ACM
Aurelius Capital Management New York $55.2M AUM 124.79% 1-Year Est. Return
SGA
Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return
NCFG
New Century Financial Group Princeton, New Jersey $56.3M AUM 16.99% 1-Year Est. Return
LAM
Lingohr Asset Management Duesseldorf, Germany $57.3M AUM 35.27% 1-Year Est. Return
ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
ITVII
IDG Technology Venture Investment IV Hong Kong $58.3M AUM 89.42% 1-Year Est. Return
MCP
Maso Capital Partners Hong Kong $60.9M AUM 0.32% 1-Year Est. Return

Qiming U.S. Ventures Management's Q4 2024 Portfolio in Review

As of Q4 2024, Qiming U.S. Ventures Management held 6 positions worth $51.1M, down 0.42% from $51.4M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q4 2024: portfolio turnover was 0%. Qiming U.S. Ventures Management opened no new positions and made no exits, leaving the 6-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Qiming U.S. Ventures Management's biggest Q4 2024 reduction was HilleVax, cutting an estimated $350K.
  • Qiming U.S. Ventures Management's ten largest holdings make up 100% of its $51.1M portfolio in Q4 2024.
  • Qiming U.S. Ventures Management opened 0 new positions and closed 0 in Q4 2024.
  • Qiming U.S. Ventures Management's portfolio value fell 0.42% quarter-over-quarter to $51.1M.

Based on Qiming U.S. Ventures Management's 13F filing for Q4 2024, filed 28 Jan 2025.